Royalties on Licensed Products. As consideration for its exclusive rights with respect to Licensed Products and the other rights provided and activities performed by Lexicon hereunder, Genentech agrees to pay Lexicon a royalty of [**] of Net Sales of each Licensed Product by Genentech, its Affiliates and Product Licensees, on a country-by-country basis, during the period commencing with the first sale for use or consumption by the general public of a Product in a country after Regulatory Approval in such country and ending on the date that is [**] from the date of such first commercial sale of such Licensed Product in such country; provided that, in the event the worldwide Net Sales of such Licensed Product for which a royalty is payable to Lexicon hereunder exceeds [**] in any Calendar Year, Genentech shall pay Lexicon a royalty of [**] on that portion of such Net Sales of such Licensed Product that exceeds [**] in such Calendar Year. The royalty payable hereunder shall be payable only once with respect to the same unit of Licensed Product.
Royalties on Licensed Products. BioNanomatrix shall pay to Princeton a royalty of […***…] of Net Sales of Licensed Products, during the term of this Agreement. Sales among BioNanomatrix, its Affiliates and its sublicensees for ultimate third party use shall be disregarded for purposes of computing royalties. Royalties shall be payable only upon sales or transfers between unrelated third parties and shall be based on arms length consideration. Notwithstanding anything to the contrary contained herein, in the event that a Licensed Product is also covered by valid claim of a patent right or is also developed, made, sold, registered or practiced using a method licensed from Princeton pursuant to a separate agreement, then BioNanomatrix shall only be required to pay to Princeton […***…].
Royalties on Licensed Products. ONCOMED shall pay to MORPHOSYS a royalty on Net Sales for each Licensed Product, on a country-by-country basis as from the date of the First Commercial Sale in each such country, and until the later of (i) [***] from the First Commercial Sale of such Licensed Product in such country; and (ii) the expiration in such country of the last Valid Claim that covers the manufacture, sale, import or use of such Licensed Product, as follows: For amounts up to EURO [***] [***] For amounts over EURO [***] [***] provided, however, in no case shall the obligation to pay a royalty exceed [***] from the first (1st) sale of a Licensed Therapeutic Product in the Territory.
Royalties on Licensed Products. (including those sold by Sub-Licensees)
(a) Licensee or Sub-Licensee sales of each Licensed Product which uses, or incorporates or its development makes us of a Data-Based Patent: 1.5% of the Net Sales Value invoiced by the Licensee or Sub-Licensee; and
(b) Licensee or Sub-Licensee sales of each Licensed Product which uses, or incorporates or its development makes us of a Technology-Based Patent: 0.375% of the Net Sales Value invoiced by the Licensee or Sub-Licensee. The royalty rate in each case is not subject to any kind of reduction including stacking.
Royalties on Licensed Products. During the Term, Isis will pay CSHL a royalty of [***]% on Net Sales of each and any single Licensed Product. Isis will pay CSHL such royalties on Net Sales for Licensed Products until the expiration of the last Valid Claim within the CSHL Patent Rights covering the manufacture, use, or sale of such Licensed Product in such country.
Royalties on Licensed Products. GPC shall pay to MORPHOSYS a royalty on Net Sales of Licensed Products sold by GPC or its Affiliates as follows: ***% on annual gross sales under DM ***; ***% on annual gross sales between DM *** and DM ***; ***% on annual gross sales over DM ***;
Royalties on Licensed Products. Each Party shall pay to the other the following percentage royalties on all Net Sales of Licensed Products in the Territory by such Party (or its associated Selling Parties) on a Licensed-Product-by-Licensed-Product basis during the Term for each such Licensed Product in accordance with Section 7.11:
Royalties on Licensed Products. IMMUNOGEN shall pay to MORPHOSYS a royalty on Net Sales of Licensed Products sold by IMMUNOGEN or its Affiliates or Sublicensees for prophylactic or therapeutic use as follows: [__________________________________] [__________________________________] [__________________________________]
Royalties on Licensed Products. If Licensee leases Licensed Product instead of selling or having others sell on their behalf, or if a lease of Licensed Product otherwise occurs under this Agreement, then Licensee shall be obligated to pay Licensor royalties at a rate of 20 percent of Gross Lease Profit. Gross Lease Profit is defined as the monthly lease price minus the cost of 106 Licensed Product sold which will include the monthly depreciation cost for the Licensed Product as well as depreciation on backup units of Licensed Products, plus the cost of servicing the leased units of Licensed Product. The cost of such servicing shall not exceed 20 percent of the net lease revenues derived from Licensee by lease of Licensed Products. Such treatment of leasing for determination of royalties shall not apply where third party pays Licensee and acts as a financial leasing agent, or where Licensee actually receives payments on a basis other than the actual lease payments. In such cases royalties are determined based on the amount and timing of payments received by Licensee and not those received by any financing and leasing organization.
Royalties on Licensed Products. (including those sold by Sub-Licensees)
(a) [####]; and
(b) [####]. [####].
